Drug Information
Drug General Information | |||||
---|---|---|---|---|---|
Drug ID |
D0K5UF
|
||||
Former ID |
DIB019609
|
||||
Drug Name |
compound 8e
|
||||
Drug Type |
Small molecular drug
|
||||
Indication | Discovery agent | Investigative | [1] | ||
Structure |
![]() |
Download2D MOL |
|||
Formula |
C22H23FN6O3S
|
||||
InChI |
InChI=1S/C22H23FN6O3S/c1-12-19(33-21(28-12)22(3,31)11-30)14-8-18(20(24)25-10-14)32-13(2)16-9-15(23)4-5-17(16)29-26-6-7-27-29/h4-10,13,30-31H,11H2,1-3H3,(H2,24,25)/t13-,22-/m1/s1
|
||||
InChIKey |
DIXMBHMNEHPFCX-MCMMXHMISA-N
|
||||
PubChem Compound ID | |||||
PubChem Substance ID | |||||
Target and Pathway | |||||
Target(s) | fer (fps/fes related) tyrosine kinase | Target Info | Inhibitor | [1] | |
ALK tyrosine kinase receptor | Target Info | Inhibitor | [1] | ||
leukocyte receptor tyrosine kinase | Target Info | Inhibitor | [1] | ||
BDNF/NT-3 growth factors receptor | Target Info | Inhibitor | [1] | ||
FES proto-oncogene, tyrosine kinase | Target Info | Inhibitor | [1] | ||
ROS1 | Target Info | Inhibitor | [1] | ||
KEGG Pathway | Non-small cell lung cancerhsa04010:MAPK signaling pathway | ||||
Neurotrophin signaling pathway | |||||
Alcoholism | |||||
Pathway Interaction Database | SHP2 signaling | ||||
Posttranslational regulation of adherens junction stability and dissassembly | |||||
Neurotrophic factor-mediated Trk receptor signaling | |||||
Reactome | NGF-independant TRKA activation | ||||
WikiPathways | Differentiation PathwayWP706:SIDS Susceptibility Pathways | ||||
BDNF signaling pathwayWP2431:Spinal Cord Injury | |||||
References | |||||
REF 1 | Design of potent and selective inhibitors to overcome clinical anaplastic lymphoma kinase mutations resistant to crizotinib. J Med Chem.> 2014 Feb 27;57(4):1170-87. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.